Rapid, sensitive test for the early diagnosis of inhalation anthrax
First FDA cleared product based on the Company's proprietary MultiPath technology
Funding Supports Continued Development of the SensiTox™ B. anthracis Toxin Test
Life Sciences Veteran Andrew Wilsack Joins Team
New videos include 1-1 clinician interviews and detailed product tour
Additional funds to support the company's diagnostic platform initiatives
Industry Experts to Support Development and Commercialization
Company Presents New Method for Rapidly Determining the Effective Antibiotics to Treat Serious Infections Directly from Patient Samples